222 related articles for article (PubMed ID: 14968076)
1. [Ciliary body melanomas. Survival and prognostic aspects after brachytherapy or proton therapy].
Gambrelle J; Kodjikian L; Rouberol F; Donate D; Duquesne N; Jean-Louis B; Chauvel P; Gérard JP; Romestaing P; Grange JD
J Fr Ophtalmol; 2004 Jan; 27(1):40-7. PubMed ID: 14968076
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant proton beam irradiation vs. adjuvant ruthenium brachytherapy in transscleral resection of uveal melanoma.
Böker A; Pilger D; Cordini D; Seibel I; Riechardt AI; Joussen AM; Bechrakis NE
Graefes Arch Clin Exp Ophthalmol; 2018 Sep; 256(9):1767-1775. PubMed ID: 29907945
[TBL] [Abstract][Full Text] [Related]
3. Plaque radiotherapy of uveal melanoma with predominant ciliary body involvement.
Gündüz K; Shields CL; Shields JA; Cater J; Freire JE; Brady LW
Arch Ophthalmol; 1999 Feb; 117(2):170-7. PubMed ID: 10037560
[TBL] [Abstract][Full Text] [Related]
4. Ruthenium brachytherapy for uveal melanoma, 1979-2003: survival and functional outcomes in the Swedish population.
Bergman L; Nilsson B; Lundell G; Lundell M; Seregard S
Ophthalmology; 2005 May; 112(5):834-40. PubMed ID: 15878063
[TBL] [Abstract][Full Text] [Related]
5. Plaque radiotherapy for management of ciliary body and choroidal melanoma with extraocular extension.
Gündüz K; Shields CL; Shields JA; Cater J; Brady L
Am J Ophthalmol; 2000 Jul; 130(1):97-102. PubMed ID: 11004266
[TBL] [Abstract][Full Text] [Related]
6. No differences in the long-term prognosis of iris and choroidal melanomas when adjusting for tumor thickness and diameter.
Sabazade S; Herrspiegel C; Gill V; Stålhammar G
BMC Cancer; 2021 Nov; 21(1):1270. PubMed ID: 34819035
[TBL] [Abstract][Full Text] [Related]
7. Ruthenium plaque radiation therapy for iris and iridociliary melanomas.
Razzaq L; Keunen JE; Schalij-Delfos NE; Creutzberg CL; Ketelaars M; de Keizer RJ
Acta Ophthalmol; 2012 May; 90(3):291-6. PubMed ID: 20670343
[TBL] [Abstract][Full Text] [Related]
8. Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years' experience with beta-rays).
Rouberol F; Roy P; Kodjikian L; Gérard JP; Jean-Louis B; Grange JD
Am J Ophthalmol; 2004 May; 137(5):893-900. PubMed ID: 15126155
[TBL] [Abstract][Full Text] [Related]
9. The American Brachytherapy Society recommendations for brachytherapy of uveal melanomas.
Nag S; Quivey JM; Earle JD; Followill D; Fontanesi J; Finger PT;
Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):544-55. PubMed ID: 12738332
[TBL] [Abstract][Full Text] [Related]
10. Ruthenium brachytherapy for uveal melanomas: Factors affecting the development of radiation complications.
Pagliara MM; Tagliaferri L; Azario L; Lenkowicz J; Lanza A; Autorino R; Caputo CG; Gambacorta MA; Valentini V; Blasi MA
Brachytherapy; 2018; 17(2):432-438. PubMed ID: 29275868
[TBL] [Abstract][Full Text] [Related]
11. 20-year assessment of metastatic latency and subsequent time to death after proton therapy for uveal melanomas.
Bellocq D; Roy P; Kodjikian L; Mathis T; Nguyen AM; Herault J; Rivoire M; Négrier S; Thariat J; Grange JD
Melanoma Res; 2020 Jun; 30(3):272-278. PubMed ID: 30320630
[TBL] [Abstract][Full Text] [Related]
12. [High-dose 106Ruthenium plaque brachytherapy for posterior uveal melanoma. A clinico-pathologic study].
Heindl LM; Lotter M; Strnad V; Sauer R; Naumann GO; Knorr HL
Ophthalmologe; 2007 Feb; 104(2):149-57. PubMed ID: 17123048
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of Ru-106/Rh-106 brachytherapy for posterior uveal melanoma.
Lommatzsch PK; Werschnik C; Schuster E
Graefes Arch Clin Exp Ophthalmol; 2000 Feb; 238(2):129-37. PubMed ID: 10766281
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors for survival after enucleation for choroidal and ciliary body melanomas.
Isager P; Ehlers N; Overgaard J
Acta Ophthalmol Scand; 2004 Oct; 82(5):517-25. PubMed ID: 15453846
[TBL] [Abstract][Full Text] [Related]
15. Long-term risk of local failure after proton therapy for choroidal/ciliary body melanoma.
Gragoudas ES; Lane AM; Munzenrider J; Egan KM; Li W
Trans Am Ophthalmol Soc; 2002; 100():43-8; discussion 48-9. PubMed ID: 12545676
[TBL] [Abstract][Full Text] [Related]
16. Plaque radiotherapy for large posterior uveal melanomas (> or =8-mm thick) in 354 consecutive patients.
Shields CL; Naseripour M; Cater J; Shields JA; Demirci H; Youseff A; Freire J
Ophthalmology; 2002 Oct; 109(10):1838-49. PubMed ID: 12359604
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of 100 melanomas of the choroid and ciliary body treated by application of ruthenium (RU 106 Rh 106)].
Grange JD; Gerard JP; Ragab M; Quintero P; Delaroche G; Jean-Louis B; Sentenac I; Fontaniere B; Bievelez B
Bull Soc Ophtalmol Fr; 1989 May; 89(5):679-82. PubMed ID: 2590984
[TBL] [Abstract][Full Text] [Related]
18. Plaque radiation therapy for malignant melanoma of the iris and ciliary body.
Finger PT
Am J Ophthalmol; 2001 Sep; 132(3):328-35. PubMed ID: 11530044
[TBL] [Abstract][Full Text] [Related]
19. Survival after proton-beam irradiation of uveal melanomas.
Kodjikian L; Roy P; Rouberol F; Garweg JG; Chauvel P; Manon L; Jean-Louis B; Little RE; Sasco AJ; Grange JD
Am J Ophthalmol; 2004 Jun; 137(6):1002-10. PubMed ID: 15183783
[TBL] [Abstract][Full Text] [Related]
20. Maximizing local tumor control and survival after proton beam radiotherapy of uveal melanoma.
Egger E; Schalenbourg A; Zografos L; Bercher L; Boehringer T; Chamot L; Goitein G
Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):138-47. PubMed ID: 11516863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
